Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952675526> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2952675526 endingPage "449" @default.
- W2952675526 startingPage "449" @default.
- W2952675526 abstract "Introduction: Lymphoblastic lymphoma (LBL) are the second most commun subtype of non-hodgkin lymphoma (NHL) in children and adolescents. The aim of this study was to characterize the clinical course of children and adolescents with LBL treated in our department. Patients and Methods: This is a retrospective study concerning patients aged 25 years or younger with LBL admitted between January 2009 and August 2018 in the hematology department of Hedi Chaker Hospital of Sfax, Tunisia. Patients were treated according to the EORTC protocol used for pediatric acute lymphoblastic leucemia. Diagnosis was based on biopsy of tumor for all patients. We analyzed in our study complete remission, relapse, death and the event free survival (EFS: using Kaplan-Meier method). Results: We collected 12 children and adolescents with LBL. The median age at diagnosis was 8 years (range, 2- 23 years). There was a predominance of males. LBL had T-cell type in 10 patients (83%). The most common primary manifestation in T-cell LBL was mediastinal involvement, in 9 patients (90%). Testicular involvment was the manifestation in 2 patients with precursor B-LBL. A cutaneous tumor was the initial manifestation in one patient with B-LBL. Seven patients (58%) had advanced disease (Stage III or IV) at diagnosis. Eleven patients (92%) achieved complete clinical remission and one patient was not evaluable (died at day 14 of induction course). After a median follow-up of 69 months, 8 patients (67%) were alive in first complete remission. Four children (33%) died, one of them soon after admission and three after relapsing. At 5 years of follow up, EFS was 72%. Conclusion: LBL comprise approximately 30% of the NHL that occur in children and young adults. In the literature, the most frequent phenotype was T (85 - 90%) similar to in our study. During the last decades, several systematic clinical trials contributed to the controlled optimization of treatment. Using acute lymphoblastic leukemia type treatment regimen to treat children with LBL was an important development in the treatment with EFS can be achieved 75-90%. Our findings confirm the favorable prognosis of children with LBL with an intensive chemotherapy regimen derived from ALL therapy. Keywords: non-Hodgkin lymphoma (NHL)." @default.
- W2952675526 created "2019-06-27" @default.
- W2952675526 creator A5001360263 @default.
- W2952675526 creator A5001702374 @default.
- W2952675526 creator A5002016519 @default.
- W2952675526 creator A5011684152 @default.
- W2952675526 creator A5013835333 @default.
- W2952675526 creator A5030931728 @default.
- W2952675526 creator A5035755122 @default.
- W2952675526 creator A5049435131 @default.
- W2952675526 creator A5051956051 @default.
- W2952675526 creator A5059218186 @default.
- W2952675526 creator A5067377366 @default.
- W2952675526 creator A5078433760 @default.
- W2952675526 creator A5080327314 @default.
- W2952675526 creator A5082113985 @default.
- W2952675526 date "2019-06-01" @default.
- W2952675526 modified "2023-10-14" @default.
- W2952675526 title "OUTCOME OF CHILDREN AND ADOLESCENTS WITH LYMPHOBLASTIC LYMPHOMA TREATED WITH THE EORTC 58951 PROTOCOL" @default.
- W2952675526 doi "https://doi.org/10.1002/hon.124_2631" @default.
- W2952675526 hasPublicationYear "2019" @default.
- W2952675526 type Work @default.
- W2952675526 sameAs 2952675526 @default.
- W2952675526 citedByCount "0" @default.
- W2952675526 crossrefType "journal-article" @default.
- W2952675526 hasAuthorship W2952675526A5001360263 @default.
- W2952675526 hasAuthorship W2952675526A5001702374 @default.
- W2952675526 hasAuthorship W2952675526A5002016519 @default.
- W2952675526 hasAuthorship W2952675526A5011684152 @default.
- W2952675526 hasAuthorship W2952675526A5013835333 @default.
- W2952675526 hasAuthorship W2952675526A5030931728 @default.
- W2952675526 hasAuthorship W2952675526A5035755122 @default.
- W2952675526 hasAuthorship W2952675526A5049435131 @default.
- W2952675526 hasAuthorship W2952675526A5051956051 @default.
- W2952675526 hasAuthorship W2952675526A5059218186 @default.
- W2952675526 hasAuthorship W2952675526A5067377366 @default.
- W2952675526 hasAuthorship W2952675526A5078433760 @default.
- W2952675526 hasAuthorship W2952675526A5080327314 @default.
- W2952675526 hasAuthorship W2952675526A5082113985 @default.
- W2952675526 hasConcept C126322002 @default.
- W2952675526 hasConcept C141071460 @default.
- W2952675526 hasConcept C146357865 @default.
- W2952675526 hasConcept C151730666 @default.
- W2952675526 hasConcept C167135981 @default.
- W2952675526 hasConcept C187212893 @default.
- W2952675526 hasConcept C194409129 @default.
- W2952675526 hasConcept C203014093 @default.
- W2952675526 hasConcept C2775934546 @default.
- W2952675526 hasConcept C2776090121 @default.
- W2952675526 hasConcept C2776694085 @default.
- W2952675526 hasConcept C2777478502 @default.
- W2952675526 hasConcept C2779338263 @default.
- W2952675526 hasConcept C3018657049 @default.
- W2952675526 hasConcept C71924100 @default.
- W2952675526 hasConcept C86803240 @default.
- W2952675526 hasConcept C8891405 @default.
- W2952675526 hasConceptScore W2952675526C126322002 @default.
- W2952675526 hasConceptScore W2952675526C141071460 @default.
- W2952675526 hasConceptScore W2952675526C146357865 @default.
- W2952675526 hasConceptScore W2952675526C151730666 @default.
- W2952675526 hasConceptScore W2952675526C167135981 @default.
- W2952675526 hasConceptScore W2952675526C187212893 @default.
- W2952675526 hasConceptScore W2952675526C194409129 @default.
- W2952675526 hasConceptScore W2952675526C203014093 @default.
- W2952675526 hasConceptScore W2952675526C2775934546 @default.
- W2952675526 hasConceptScore W2952675526C2776090121 @default.
- W2952675526 hasConceptScore W2952675526C2776694085 @default.
- W2952675526 hasConceptScore W2952675526C2777478502 @default.
- W2952675526 hasConceptScore W2952675526C2779338263 @default.
- W2952675526 hasConceptScore W2952675526C3018657049 @default.
- W2952675526 hasConceptScore W2952675526C71924100 @default.
- W2952675526 hasConceptScore W2952675526C86803240 @default.
- W2952675526 hasConceptScore W2952675526C8891405 @default.
- W2952675526 hasIssue "S2" @default.
- W2952675526 hasLocation W29526755261 @default.
- W2952675526 hasOpenAccess W2952675526 @default.
- W2952675526 hasPrimaryLocation W29526755261 @default.
- W2952675526 hasRelatedWork W2003938723 @default.
- W2952675526 hasRelatedWork W2047967234 @default.
- W2952675526 hasRelatedWork W2089034243 @default.
- W2952675526 hasRelatedWork W2118496982 @default.
- W2952675526 hasRelatedWork W2176318035 @default.
- W2952675526 hasRelatedWork W2369557997 @default.
- W2952675526 hasRelatedWork W2439875401 @default.
- W2952675526 hasRelatedWork W3031808705 @default.
- W2952675526 hasRelatedWork W911446555 @default.
- W2952675526 hasRelatedWork W2184873327 @default.
- W2952675526 hasVolume "37" @default.
- W2952675526 isParatext "false" @default.
- W2952675526 isRetracted "false" @default.
- W2952675526 magId "2952675526" @default.
- W2952675526 workType "article" @default.